Specificity of autoantibodies to epitopes of myelin proteins in multiple sclerosis

Journal of the Neurological Sciences

Volumn 206, Issue 1, 2003, Pages 7-16

  Dharmasaroja, Permphan ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Epitope mapping; Epitope specificity; Immunoglobulins; Multiple sclerosis; Myelin basic protein; Myelin oligodendrocyte glycoprotein; Myelin proteins; Myelin proteolipid protein

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; AMINO ACID; AUTOANTIBODY; EPITOPE; GALACTOSYLCERAMIDE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN PROTEIN; PROLINE; PROTEOLIPID PROTEIN;

MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW;

ANTIBODY SPECIFICITY; AUTOANTIBODIES; EPITOPES; HUMANS; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN PROTEINS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 0037437662     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00349-0     Document Type: Review

References (120)

1. Whitaker J.N., Mitchell G.W. Clinical feature of multiple sclerosis. Raine C.S., McFarland H.R., Tourtellotte W.W. Multiple sclerosis: clinical and pathogenetic basis. 1997;3-19 Chapman & Hall, London.
2. Linington C., Bradl M., Lassmann H.et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J. Pathol. 130:1988;443-454.
3. Genain C.P., Ngnyen M.H., Letvin N.L.et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 96:1995;2966-2977.
4. Storch M.K., Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr. Opin. Neurol. 10:1997;186-192.
5. Brosnan C.F., Raine C.R. Mechanism of immune injury in multiple sclerosis. Brain Pathol. 6:1996;243-257.
6. Piddlesden S.J., Lassmann H., Zimprich F.et al. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J. Pathol. 143:1993;555-564.
7. Storch M.K., Piddlesden S.J., Haltia M.et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43:1998;465-471.
8. Muller D.M., Pender M.P., Greer J.M. A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. Acta Neuropathol. (Berl.). 100:2000;174-182.
9. Hjelmstrom P., Juedes A.E., Fjell J., Ruddle N.H. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J. Immunol. 161:1998;4480-4483.
10. Sellebjerg F., Jensen C.V., Christiansen M. Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis. J. Neuroimmunol. 108:2000;207-215.
11. Olsson T., Kostulas V., Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin. Chem. 30:1984;1246-1249.
12. Panitch H.S., Hooper C.S., Johnson K.P. CSF antibody to myelin basic protein: measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch. Neurol. 37:1980;206-209.
13. Gorny M.K., Wroblewska Z., Pleasure D.et al. CSF antibody to myelin basic protein and oligodendrocytes in multiple sclerosis and other neurological diseases. Acta Neurol. Scand. 67:1983;338-347.
14. Wajgt A., Gorny M. CSF antibodies to myelin basic protein and to myelin-associated glycoprotein in multiple sclerosis: evidence of the intrathecal production of antibodies. Acta Neurol. Scand. 68:1983;337-343.
15. Cruz M., Olsson T., Ernerudt J.et al. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology. 37:1987;1515-1519.
16. Link H., Baig S., Olsson O.et al. Persistent anti-myelin basic protein IgG antibody response in multiple sclerosis cerebrospinal fluid. J. Neuroimmunol. 28:1990;237-248.
17. Olsson T., Sun J., Hillert J.et al. Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur. J. Immunol. 22:1992;1083-1087.
18. Moller J.R., Johnson D., Brady R.O.et al. Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 22:1989;55-61.
19. Xiao B.G., Linington C., Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J. Neuroimmunol. 31:1991;91-96.
20. Warren K.G., Catz I. Relation frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J. Neurol. Sci. 121:1994;66-73.
21. Wucherpfennig K.W., Catz I., Hausmann S.et al. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J. Clin. Invest. 100:1997;1114-1122.
22. Walsh M.J., Murray J.M. Dual implication of 2′,3′-cyclic nucleotide 3′ phosphodiesterase as a major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J. Clin. Invest. 101:1998;1923-1931.
23. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:1999;170-175.
24. Raine C.S., Cannella B., Hauser S.L., Genain C.P. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 46:1999;144-160.
25. Archelos J.J., Storch M.K., Hartung H-P. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47:2000;694-706.
26. Zhao Y., Chalt B.T. Protein epitope mapping by mass spectrometry. Anal. Chem. 66:1994;3723-3726.
27. Harper D.R. Viral interactions with the immune system. Harper D.R. Molecular virology. 2nd ed. 1998;53-79 IOS Scientific, London.
28. Warren K.G., Catz I. A correlation between cerebrospinal fluid myelin basic protein and anti-myelin basic protein in multiple sclerosis patients. Ann. Neurol. 21:1987;183-189.
29. Warren K.G., Catz I. Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis. Ann. Neurol. 20:1986;20-25.
30. Warren K.G., Catz I. Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid. J. Neuroimmunol. 39:1992;81-89.
31. Warren K.G., Catz I. Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis. J. Neuroimmunol. 43:1993;87-96.
32. Warren K.G., Catz I., Johnson E., Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann. Neurol. 35:1994;280-289.
33. Reindl M., Linington C., Brehm U.et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain. 122:1999;2047-2056.
34. Martino G., Olsson T., Fredrikson S.et al. Cells producing antibodies specific for myelin basic protein 70-89 are predominant in cerebrospinal fluid from patients with multiple sclerosis. Eur. J. Immunol. 21:1991;2971-2976.
35. Sellebjerg F., Christiansen M., Garred P. MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Mult. Scler. 4:1998;127-131.
36. Egg R., Reindl M., Deisenhammer F.et al. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult. Scler. 7:2001;285-289.
37. Warren K.G., Catz I., Steinman L. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B cell epitope and a model of its feature. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11061-11065.
38. Wucherpfennig K.W., Settle A., Southwood S.et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179:1994;279-290.
39. Martin R., Howell M.D., Jaraquemada D.et al. A myelin basic protein peptide is recognized by T cells in the context of four HLA-DR types associated with multiple sclerosis. J. Exp. Med. 173:1991;19-24.
40. Sedzik J., Blaurock A.E., Hochli M. Lipid/myelin basic protein multilayers. A model for the cytoplastic space in central nervous system myelin. J. Mol. Biol. 174:1984;385-409.
41. Kamholz J., de Ferra F., Puckett C., Lazzarini R. Identification of three forms of human myelin basic protein by cDNA cloning. Proc. Natl. Acad. Sci. U. S. A. 83:1986;4962-4966.
42. Stoner G.L. Predicted folding of beta-structure in myelin basic protein. J. Neurochem. 43:1984;433-447.
43. Martenson R.E. Possible hydrophobic region in myelin basic protein consisting of an orthogonally packed beta-sheet. J. Neurochem. 46:1986;1612-1622.
44. Inouye H., Kirschner D.A. Folding and function of the myelin proteins from primary sequence data. J. Neurosci. Res. 28:1991;1-17.
45. Ridsdale R.A., Beniac D.R., Tompkins T.A.et al. Three-dimensional structure of myelin basic protein: II. Molecular modeling and considerations of predicted structures in multiple sclerosis. J. Biol. Chem. 272:1997;4269-4275.
46. Creighton T.E. Creighton T.E. Proteins: structure and molecular principles. 2nd ed. 1993;1-46 Freeman, NewYork.
47. Stryer L. Stryer L. Biochemistry. 3rd ed. 1988;15-42 Freeman, NewYork.
48. Moscarello M.A., Wood D.D., Ackerley C., Boulias C. Myelin in multiple sclerosis is developmentally immature. J. Clin. Invest. 94:1994;146-154.
49. Wood D.D., Bilbao J.M., O'Connors P., Moscarello M.A. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann. Neurol. 40:1996;18-24.
50. Tuohy V.K., Lu Z., Sobel R.A.et al. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142:1989;1523-1527.
51. Greer J.M., Kuchroo V.K., Sobel R.A., Lees M.B. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. J. Immunol. 149:1992;783-788.
52. Tuohy V.K., Thomas D.M. Sequence 104-117 of myelin proteolipid protein is a cryptic encephalitogenic T cell determinant for SJL/J mice. J. Neuroimmunol. 56:1995;161-170.
53. Greer J.M., Sobel R.A., Sette A.et al. Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J. Immunol. 156:1996;371-379.
54. Whitham R.H., Jones R.E., Hashim G.A.et al. Location of a new encephalitogenic epitope (residues 43 to 64) in proteolipid protein that induces relapsing experimental autoimmune encephalitomyelitis in PL/J and (SJL×PL)F1 mice. J. Immunol. 147:1991;3803-3808.
55. Linington C., Gunn C.A., Lassmann H. Identification of an encephalitogenic determinant of myelin proteolipid protein for the rabbit. J. Neuroimmunol. 30:1990;135-144.
56. Potter N.T., Stephens T.S. Humoral immune recognition of proteolipid protein (PLP)-specific encephalitogenic epitopes in the SJL/J mouse. J. Neurosci. Res. 37:1994;15-22.
57. Wang L.Y., Fujinami R.S. Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein. J. Neuroimmunol. 75:1997;75-83.
58. Pelfrey C.M., Trotter J.L., Tranquill L.R., McFarland H.F. Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytotoxic CD4+ T cells from multiple sclerosis patients. J. Neuroimmunol. 46:1993;33-42.
59. Pelfrey C.M., Trotter J.L., Tranquill L.R., McFarland H.F. Identification of a second T cell epitope of human proteolipid protein (residues 89-106) recognized by proliferative and cytotoxic CD4+ T cells from multiple sclerosis patients. J. Neuroimmunol. 53:1994;153-161.
60. Markovic-Pless S., Fukaura H., Zhang J.et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J. Immunol. 155:1995;982-992.
61. Greer J.M., Csurhes P.A., Cameron K.D.et al. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain. 120:1997;1447-1460.
62. Pender M.P., Csurhes P.A., Greer J.M.et al. Surges on increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J. Immunol. 165:2000;5322-5331.
63. Tuohy V.K., Yu M., Weinstock-Guttman B., Kinkel R.P. Diversity and plasticity of self recognition during the development of multiple sclerosis. J. Clin. Invest. 99:1997;1682-1690.
64. Tuohy V.K., Yu M., Yin L.et al. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J. Autoimmun. 13:1999;11-20.
65. Laman J.D., Visser L., Maassen C.B.et al. Novel monoclonal antibodies against proteolipid protein peptide 139-151 demonstrate demyelination and myelin uptake by macrophages in MS and marmoset EAE lesions. J. Neuroimmunol. 119:2001;124-130.
66. Greer J.M., Denis B., Sobel R.A., Trifilieff E. Thiopalmitoylation of myelin proteolipid protein epitopes enhances immunogenicity and encephalitogenicity. J. Immunol. 166:2001;6907-6913.
67. Tuohy V.K., Lu Z., Sobel R.A.et al. A synthetic peptide from myelin proteolipid protein induces experimental allergic encephalitomyelitis. J. Immunol. 141:1988;1126-1130.
68. Ohashi T., Yamamua T., Inobe J.et al. Analysis of proteolipid protein (PLP)-specific T cells in multiple sclerosis: identification of PLP95-116 as an HLA-DR2, w15-associated determinant. Int. Immunol. 7:1995;1771-1778.
69. Pelfrey C.M., Tranquill L.R., Vogt A.B., McFarland H.F. T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls. Mult. Scler. 1:1996;270-278.
70. Trotter J.L., Pelfrey C.M., Trotter A.L.et al. T cell recognition of myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J. Neuroimmunol. 84:1998;172-178.
71. Pelfrey C.M., Rudick R.A., Cotleur A.C.et al. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 165:2000;1641-1651.
72. Ichikawa M., Johns T.G., Liu J., Bernard C.C. Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rat injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55. J. Immunol. 157:1996;19-26.
73. Bernard C.C., Johns T.G., Slavin A.et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J. Mol. Med. 75:1997;77-88.
74. Berger T., Reindl M. Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis. J. Neural. Transm., Suppl. 60:2000;351-360.
75. Amor S., Groome N., Linington C.et al. Identification of epitope of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J. Immunol. 153:1994;4349-4356.
76. Ichikawa M., Johns T.G., Adelmann M., Bernard C.C. Antibody response in Lewis rats injected with myelin oligodendocyte glycoprotein derived peptides. Int. Immunol. 8:1996;1667-1674.
77. Mendel I., Kerloro de Rosbo N., Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 25:1995;1951-1959.
78. Ichikawa M., Koh C.S., Inaba Y.et al. IgG subclass switching is associated with the severity of experimental autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein peptide in NOD mice. Cell. Immunol. 191:1999;97-104.
79. Kerlero de Rosbo N., Brok H.P., Bauer J.et al. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterization of immunodominant T- and B-cell epitopes. J. Neuroimmunol. 110:2000;83-96.
80. Brok H.P., Uccelli A., Kerlero de Rosbo N.et al. Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. J. Immunol. 165:2000;1093-1101.
81. Massacesi L., Genain C.P., Lee-Parritz D.et al. Actively and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. Ann. Neurol. 37:1995;519-530.
82. Haase C.G., Guggenmos J., Brehm U.et al. The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal health controls. J. Neuroimmunol. 114:2001;220-225.
83. Kerlero de Rosbo N., Hoffman M., Mendel I.et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur. J. Immunol. 27:1997;3059-3069.
84. Lindert R.S., Haase C.G., Brehm U.et al. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain. 122:1999;2089-2100.
85. Mendel Kerlero de Rosbo N., Ben-Nun A. Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta a H-2b mice. Eur. J. Immunol. 26:1996;2470-2479.
86. Hjelmstrom P., Penzotti J.E., Henne R.M., Lybrand T.P. A molecular model of myelin oligodendrocyte glycoprotein. J. Neurochem. 71:1998;1742-1749.
87. Bettadapura J., Menon K.K., Moritz S.et al. Expression, purification and encephalitogenicity of recombinant human myelin oligodendrocyte glycoprotein. J. Neurochem. 70:1998;1593-1599.
88. Abo S., Bernard C.C.A., Webb M.et al. Preparation of highly purified human myelin oligodendrocyte glycoprotein in qualities sufficient for encephalitogenicity and immunogenicity studies. Biochem. Mol. Biol. Int. 30:1993;945-958.
89. John T.G., Bernard C.C.A. Binding of complement C1q to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol. Immunol. 34:1997;33-38.
90. Gardinier M.V., Amiguet P., Linington C., Matthieu J.M. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J. Neurosci. Res. 33:1992;177-187.
91. Rudd P.M., Dwek R.A. Glycosylation: heterogeneity and the 3D structure of proteins. Crit. Rev. Biochem. Mol. Biol. 32:1997;1-100.
92. Bork P., Holm L., Sander C. The immunoglobulin fold: structural classification, sequence patterns and common core. J. Mol. Biol. 242:1994;309-320.
93. Albouz-Abo S., Wilson J.C., Bernard C.C.A., Von Hzstein M. A conformational study of the human and rat encephalitogenic myelin oligodendrocyte glycoprotein peptides 35-55. Eur. J. Biochem. 246:1997;59-70.
94. Roth M.P., Dolbois L., Borot N.et al. Myelin oligodendrocyte glycoprotein (MOG) gene polymorphisms and multiple sclerosis: no evidence of disease association with MOG. J. Neuroimmunol. 61:1995;117-122.
95. Hilton A.A., Slavin A.J., Hilton D.J., Bernard C.C.A. Characterization of cDNA and genomic clones encoding human myelin oligodendrocyte glycoprotein. J. Neurochem. 65:1995;309-318.
96. Rodriguez D., Della Gaspera B., Zalc B.et al. Identification at a Val 145 Ile substitution in the human myelin oligodendrocyte glycoprotein: lack of association with multiple sclerosis. Mult. Scler. 3:1997;377-381.
97. Baig S., Olsson T., Jiang Y.P.et al. Multiple sclerosis: cell secreting antibodies against myelin-associated glycoprotein are present in CFS. Scand. J. Immunol. 33:1991;73-79.
98. Archelos J.J., Trotter J., Previtali S.et al. Isolation and characterization of an oligodendrocyte-precursor-derived B cell epitope in multiple sclerosis. Ann. Neurol. 43:1998;15-24.
99. Gao Y.L., Raine C.S., Brosnan C.F. Humoral response to hsp 65 in multiple sclerosis and other neurologic conditions. Neurology. 44:1994;941-946.
100. Prabhakar S., Kurien E., Gupta R.S.et al. Heat shock protein immunoreactivity in CFS: correlation with oligoclonal banding and demyelinating disease. Neurology. 44:1994;1644-1648.
101. Zenetta J.P., Tranchant C., Kuchler-Bopp S.et al. Presence of anti-CSL antibodies in the cerebrospinal fluid of patients: a sensitive and specific test in the diagnosis of multiple sclerosis. J. Neuroimmunol. 52:1944;175-182.
102. Colombo E., Banki K., Tatum A.H.et al. Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. J. Clin. Invest. 99:1997;1238-1250.
103. Bronstein J.M., Lallone R.L., Seitz R.S.et al. A humoral response to oligodendrocyte-specific protein in MS. Neurology. 53:1999;154-161.
104. Niehaus A., Shi J., Grzenkowski M.et al. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann. Neurol. 48:2000;362-371.
105. Morris-Downes M.M., McCormack K., Baker D.et al. Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in ABH and SJL mice. J. Neuroimmunol. 122:2002;20-33.
106. Maatta J.A., Kaldman M.S., Sakoda S.et al. Encephalitogenicity of myelin-associated oligodendrocytic basic protein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase for BALB/c and SJL mice. Immunology. 95:1998;383-388.
107. Bronstein J.M., Micevych P.E., Chen K. Oligodendrocyte-specific protein (OSP) is a major component of CNS myelin. J. Neurosci. Res. 50:1997;713-720.
108. Bronstein J.M., Popper P., Micevych P.E., Farber D.B. Isolation and characterization of a novel oligodendrocyte-specific protein. Neurology. 47:1996;772-778.
109. Stevens D.B., Chen K., Seitz R.S.et al. Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice. J. Immunol. 162:1999;7501-7509.
110. Saida T., Saida K., Silberberg D.H. Demyelination produced by experimental allergic neuritis serum and anti-galactocerebroside antiserum in CNS cultures. An ultrastructural study. Acta Neuropathol. (Berl.). 48:1979;19-25.
111. Moore G.R., Traugott U., Farooq M.et al. Experimental autoimmune encephalomyelitis. Augmentation of demyelination by different myelin lipids. Lab. Invest. 51:1984;416-424.
112. Khang S.K., Chi J.G., Lee S.K. A study on demyelinating effect of galactocerebroside in experimental allergic encephalomyelitis. J. Korean Med. Sci. 3:1988;89-98.
113. Kusunoki S., Yu R.K., Kim J.H. Induction of experimental autoimmune encephalomyelitis in guinea pigs using myelin basic protein and myelin glycolipids. J. Neuroimmunol. 18:1988;303-314.
114. Sadler R.H., Sommer M.A., Forno L.S., Smith M.E. Induction of anti-myelin antibodies in EAE and their possible role in demyelination. J. Neurosci. Res. 30:1991;616-624.
115. Lubetski C., Lombrail P., Hauw J.J., Zalc B. Multiple sclerosis: rat and human oligodendrocytes are not the target for CSF immunoglobulins. Neurology. 36:1986;524-528.
116. Rostami A.M., Burns J.B., Eccleston P.A.et al. Search for antibodies to galactocerebroside in the serum and cerebrospinal fluid in human demyelinating disorders. Ann. Neurol. 22:1987;381-383.
117. Yamamoto Y., Mizuno R., Nishimura T.et al. Cloning and expression of myelin-associated oligodendrocytic basic protein. A novel basic protein constituting the central nervous system myelin. J. Biol. Chem. 269:1994;31725-31730.
118. Yamamoto Y., Yoshikawa H., Nagano S.et al. Myelin-associated oligodendrocytic basic protein is essential for normal arrangement of the radial component in central nervous system myelin. Eur. J. Neurosci. 11:1999;847-855.
119. Holz A., Bielekova B., Martin R., Oldstone M.B. Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis. J. Immunol. 164:2000;1103-1109.
120. Kaye J.F., Kerlero de Rosbo N., Mendel I.et al. The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS). J. Neuroimmunol. 102:2000;189-198.